Monitor CHF Patients at Home: CoVa Monitoring System 2 by ToSense
CoVa2 is the first FDA approved device for monitoring CHF patients at home after discharge from a hospital. Hemodynamic parameters include Heart Rate, Heart Rate Variability, Stroke Volume, Cardiac Output, Respiration Rate, Skin Temperature and Single Lead ECG. CoVa2 measures changes in chest fluids via Thoracic Impedance (TEB).
CoVa can predict the potential onset of CHF episodes by as much as 2 weeks over conventional methods. In its clinical trial, CoVa reduced CHF re-admissions 84% over 6 months.
CoVa is a Class 2 medical device and may only be sold to a provider or on a prescription from a physician.